Skip to main content
Home Report Heatmap Pricing Get Started
PFE

Pfizer Inc. — Beer Score

PFE · US Equity · Healthcare — Pharmaceuticals
$27.50
Market Price (indicative) · Feb 7, 2026
+$0.35 (+1.29%) today
Reference price only. Not an official exchange feed.
86
/ 100
Solid Value — Est. 86% Fundamental Value
Updated: Feb 7, 2026 16:30 UTC·Filing: 10-K (Jan 29, 2026)·Model: DCF v1.0
Not investment advice · Model-based estimate
Estimated Value (Beer)
$23.65
86%
Est. Speculation Premium (Foam)
$3.85
14%
🍺 86% Est. Fundamental Value🫧 14% Est. Speculation
Track Score Alerts (Pro) See Model Assumptions ↓

Key Financials

TTM
Revenue$58.5B
Net Income$2.1B
Free Cash Flow$7.5B
P/E Ratio31.3x
EPS (TTM)$0.88
Market Cap$155B
Total Debt$61.2B
Cash & Equiv.$3.5B

DCF Valuation

Model Estimate
$23
Est. intrinsic value (DCF model)
vs $27.50 market price
Our model suggests the current price is ~16% above the estimated intrinsic value. The market may be pricing in growth beyond current fundamentals.
WACC8.0%
Growth Rate (5yr)6%
Terminal Growth2%
Margin of Safety~−16%

Model output varies with assumptions (WACC, growth, margins). This is not a price target or investment recommendation.

Score History — 90 Days

Pro
90d Low
80
90d High
88
Zone Changes
3

Pfizer Stock Valuation — Beer Score Breakdown

Pfizer's Beer Score of 86 means that, according to our DCF model, the stock is well-supported by fundamentals. An estimated 86% of the stock price is backed by earnings, cash flow, and assets.

How Beer Score Is Calculated for PFE

We pull Pfizer's latest SEC filings from EDGAR, run a DCF analysis using a 8.0% WACC and 6% revenue growth rate over 5 years with 2% terminal growth, then compare the resulting model estimate ($23) against the current market price ($27.50). The Beer Score of 86 represents the ratio. Model output varies with assumptions. Learn more about our methodology →

Important Information

Beer Score is an educational indicator, not investment advice. It measures the model-estimated gap between a stock's current market price and an estimated intrinsic value derived from public financial data. A low Beer Score does not mean "sell" and a high score does not mean "buy." Model output varies with assumptions (WACC, growth rate, terminal growth, margins).

Prices shown are indicative reference prices for educational purposes only and are not sourced from an official exchange feed. Data sources include SEC EDGAR filings, indicative market price data, and proprietary DCF models. Scores update daily after market close. For the full ranking of all 45 stocks, visit the Beer Score Heatmap or read Today's Foam Report.

Track Pfizer's Beer Score Over Time

Get daily score changes, alerts when foam levels shift, and full history charts with Pro.

See Pro Plans → View All 45 Stocks

About This Valuation

Why does Pfizer have a Beer Score of 83?
Pfizer (PFE) scores 83 because the stock is currently trading approximately -17% below its estimated intrinsic value of $23. With $7.5B in annual free cash flow and $58.5B in revenue, the company's fundamentals more than support the current market price of $27.58 per share. The Beer Score reflects that 83% of the price is backed by estimated fundamental value.
Is PFE overvalued or undervalued?
Based on our DCF model, Pfizer appears undervalued. The estimated intrinsic value of $23 compared to the current price of $27.58 suggests a meaningful margin of safety. This is a model-based estimate using 8.0% WACC and 6% projected growth — not a buy or sell recommendation. The actual fair value depends on assumptions that may change with new earnings data or market conditions.
What assumptions drive the $23 intrinsic value?
The DCF model uses a 8.0% weighted average cost of capital and projects 6% annual revenue growth over five years. Terminal growth is set at 2%. Starting from $7.5B in current free cash flow, these assumptions produce an estimated intrinsic value of $23 per share. The model is most sensitive to the growth rate and WACC inputs — small changes in either significantly alter the output.
What could change Pfizer's Beer Score?
Pfizer scores well because post-COVID revenue normalization has been priced in aggressively by the market. If the oncology pipeline from the Seagen acquisition delivers on schedule, intrinsic value could increase substantially. However, debt from the $43B Seagen deal limits financial flexibility. Further COVID vaccine revenue decline and potential pricing pressure from Medicare negotiation add downside risk.

Compare Similar Stocks

JNJ58 LLY17 DHR94 UNH100
View all stock valuations →